Related Experiment Video

Updated: May 5, 2026

Simultaneous Isolation of High Quality Cardiomyocytes, Endothelial Cells, and Fibroblasts from an Adult Rat Heart
09:38

Simultaneous Isolation of High Quality Cardiomyocytes, Endothelial Cells, and Fibroblasts from an Adult Rat Heart

Published on: May 19, 2017

13.4K

Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection

Takahisa Noma1, Anthony Lemaire, Sathyamangla V Naga Prasad

  • 1Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA.

The Journal of Clinical Investigation
|September 6, 2007
PubMed

Insights

Chronic beta-adrenergic receptor (betaAR) stimulation harms the heart via Gs-dependent pathways. A new beta-arrestin-mediated pathway to EGFR offers cardioprotection, suggesting novel therapeutic targets.

Area of Science:

  • Cardiovascular Science
  • Molecular Pharmacology
  • Cell Signaling

Background:

  • Chronic beta-adrenergic receptor (betaAR) stimulation typically causes heart damage through Gs-dependent adenylyl cyclase activation.
  • Understanding alternative signaling pathways is crucial for developing heart-protective therapies.

Purpose of the Study:

  • To identify and characterize a novel beta-arrestin-mediated signaling pathway initiated by beta1AR.
  • To investigate the role of this pathway in cardioprotection during chronic sympathetic stimulation.

Main Methods:

  • Utilized in vitro and in vivo experimental systems.
  • Investigated beta-arrestin-dependent transactivation of the Epidermal Growth Factor Receptor (EGFR).
  • Examined the involvement of G protein-coupled receptor kinases 5 and 6 (GRKs 5/6).

Main Results:

  • Identified a novel beta-arrestin-dependent signaling pathway where beta1AR signals to EGFR, independent of G protein activation.
  • Demonstrated that GRKs 5 and 6 are required for this beta-arrestin-mediated EGFR transactivation.
  • Showed that this pathway activates cardioprotective mechanisms counteracting catecholamine toxicity in mice.

Conclusions:

  • A novel beta-arrestin/EGFR signaling axis activated by beta1AR offers a cardioprotective effect.
  • This pathway is independent of canonical G protein signaling and involves GRKs 5/6.
  • Suggests potential for developing therapeutics targeting beta-arrestin-mediated pathways for cardiovascular protection.

More Related Videos

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery08:21

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

6.2K
BRET-based G Protein Biosensors for Measuring G Protein-Coupled Receptor Activity in Live Cells09:21

BRET-based G Protein Biosensors for Measuring G Protein-Coupled Receptor Activity in Live Cells

Published on: November 7, 2025

922

Related Concept Videos

GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
6.9K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.4K
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
3.8K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
2.2K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
2.1K